Advertisement

U.S. Markets open in 3 hrs 40 mins

S&P Futures
4,072.00
+14.50(+0.36%)
Dow Futures
33,029.00
+126.00(+0.38%)
Nasdaq Futures
13,002.75
+37.75(+0.29%)
Russell 2000 Futures
1,792.30
+8.00(+0.45%)
Crude Oil
73.42
+0.45(+0.62%)
Gold
1,984.60
+0.10(+0.01%)

Advertisement

SPDR Portfolio S&P 500 Value ETF (SPYV)

NYSEArca - NYSEArca Delayed Price. Currency in USD

39.96

+0.61

(+1.55%)

At close: 04:00PM EDT

40.67

+0.71

(+1.78%)

After hours:

07:11PM EDT

Advertisement

Trade prices are not sourced from all markets

GlobeNewswire
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for at least six months while maintaining C9orf72 protein levels Recently reported clinical data from ongoing Phase 1b/2a FOCUS-C9 trial of WVE-004 suggest these preclinical data translate in the clinic CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage gene

Advertisement